Safety and Efficacy of Iptacopan in Patients with IgA Nephropathy with Baseline eGFR 20 to &lt;30 mL/min: Phase 3 APPLAUSE-IgAN Subcohort Results

Dana V. Rizk, Dmitrij Kollins, Olympia Papachristofi, Thomas Hach, Severina Jacinto-Sanders, Tobias Merkel, Robert L. Schmouder, Kenneth M. Kulmatycki, Ronny W. Renfurm, Vlado Perkovic

doi:10.1681/asn.20241h4rz9f5

Safety and Efficacy of Iptacopan in Patients with IgA Nephropathy with Baseline eGFR 20 to <30 mL/min: Phase 3 APPLAUSE-IgAN Subcohort Results

Authors: Dana V. Rizk, Dmitrij Kollins, Olympia Papachristofi, Thomas Hach, Severina Jacinto-Sanders, Tobias Merkel, Robert L. Schmouder, Kenneth M. Kulmatycki, Ronny W. Renfurm, Vlado Perkovic

Published: 2024-10-28

DOI: 10.1681/asn.20241h4rz9f5

Keywords: No keywords found.

Abstract:
No abstract found.

Source:

Safety and Efficacy of Iptacopan in Patients with IgA Nephropathy with Baseline eGFR 20 to &lt;30 mL/min: Phase 3 APPLAUSE-IgAN Subcohort Results

Safety and Efficacy of Iptacopan in Patients with IgA Nephropathy with Baseline eGFR 20 to <30 mL/min: Phase 3 APPLAUSE-IgAN Subcohort Results